On 4th of June, 2019, Local American Working Group, together with Innovative Pharmaceutical Industry Association (IFPA), Lithuanian Society of Hematology (LHD), Lithuanian Society of Oncology (LOD) and Patient Organization “Kraujas organized” a discussion on “Determination of therapeutic value of pharmaceutical treatment of oncological diseases and the availability of such treatment in Lithuania“.
Participants of the discussion were welcomed by the Deputy Minister of Health, dr. Kristina Garuolienė. The assessment of health technologies from the evaluator’s point of view was presented by the representative of the Health Technology Assessment Division of the State Medicines Control Agency at the Ministry of Health , MD Eglė Karinauskė. Representative of Drug Compensation and Pricing Policy Department of the Ministry of Health, MD Simona Stankevičiūtė spoke about the value of medical treatment of oncological diseases and its availability in Lithuania. Patient’s approach to the new reimbursement procedure was presented by Ieva Drėgvienė, chairman of the Patient Organization “Kraujas”. The member of the Board of Lithuanian Society of Hematology (LHD) prof. dr. med. Laimonas Griškevičius and Director of Lithuanian Oncology Society (LOD) dr. Birutė Brasiūnienė presented the view on medicine’s therapeutic value and a potential economic threshold for drug evaluation.